Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Q3 FY25 revenue up 24% to Rs 3,230 crore
PAT after MI is Rs. 41 crore which is 162% increase
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Subscribe To Our Newsletter & Stay Updated
